


IN THE CLAIMS

1. (currently amended) A compound, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula I:

Formula I

wherein:

G, J and Y may be the same or different and are independently selected from the group consisting of the moieties: H, alkyl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyloxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkyl-aryl amino, arylamino, heteroaryl amino, cycloalkylamino and heterocycloalkylamino, with the proviso that Y maybe additionally optionally substituted with X¹¹ or X¹²;

X¹¹ is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, arylalkyl, heteroaryl, alkylheteroaryl, or heteroarylalkyl moiety, with the proviso that X¹¹ may be additionally optionally substituted with X¹²;

X¹² is hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy,

alkylureido, arylureido, halogen, cyano, or nitro, with the proviso that said alkyl, alkoxy, and aryl may be additionally optionally substituted with moieties independently selected from X^{12} ;

R^1 is COR^5 or $B(OR)_2$, wherein R^5 is selected from the group consisting of OH , OR^8 , with the proviso that R^8 is not alkyl, NR^9R^{10} , CF_3 , C_2F_5 , C_3F_7 , CF_2R^6 , R^6 and COR^7 wherein R^7 is selected from the group consisting of H , OH , OR^8 , CHR^9R^{10} , and $NR^9R^{10}-NHR^{10}$, wherein R^6 , R^8 , R^9 and R^{10} may be the same or different and are independently selected from the group consisting of H , alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, cycloalkyl, arylalkyl, heteroarylkyl, $CH(R^{1'})COOR^{11}$, $CH(R^{1'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})COO R^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})R'$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})COOR^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})COOR^{11}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})CONR^{12}R^{13}$, $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})CONHCH(R^{5'})COOR^{11}$, and $CH(R^{1'})CONHCH(R^{2'})CONHCH(R^{3'})CONHCH(R^{4'})CONHCH(R^{5'})CONR^{12}R^{13}$, wherein $R^{1'}$, $R^{2'}$, $R^{3'}$, $R^{4'}$, $R^{5'}$, R^{11} , R^{12} , R^{13} , and R' may be the same or different and are independently selected from a group consisting of H , alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl and heteroaralkyl;

Z is selected from O , N , or CH ;

W maybe present or absent, and if W is present, W is selected from $C=O$, $C=S$, or SO_2 ; and

R, R', R², R³ and R⁴ are independently selected from the group consisting of H; C1-C10 alkyl; C2-C10 alkenyl; C3-C8 cycloalkyl; C3-C8 heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino other than for R², amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro; oxygen, nitrogen, sulfur, or phosphorus atoms (with said oxygen, nitrogen, sulfur, or phosphorus atoms numbering zero to six); (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, wherein said cycloalkyl is made of three to eight carbon atoms, and zero to six oxygen, nitrogen, sulfur, or phosphorus atoms, and said alkyl is of one to six carbon atoms; aryl; heteroaryl; alkyl-aryl; and alkyl-heteroaryl;
wherein said alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties may be optionally substituted, with said term "substituted" referring to optional and chemically-suitable substitution with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclic, halogen, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, sulfonamide, sulfoxide, sulfone, sulfonylurea, hydrazide, and hydroxamate; with the proviso that R² is not arylalkyl or cyclohexylalkyl.

2. (currently amended) The compound of claim 1 wherein R¹ is COR⁵, and R⁵ is OH—COOR⁸ or CONR⁹R¹⁰.

3. (previously presented) The compound of claim 2, wherein R¹ is COCONR⁹R¹⁰, and R⁹ is H, R¹⁰ is selected from the group consisting of H, CH(R^{1'})COOR¹¹, CH(R^{1'})CONR¹²R¹³, CH(R^{1'})CONHCH(R^{2'})COOR¹¹, CH(R^{1'})CONHCH(R^{2'})CONR¹²R¹³, and CH(R^{1'})CONHCH(R^{2'})(R').

4. (original) The compound of claim 3, wherein R¹⁰ is CH(R^{1'})CONHCH(R^{2'})COOR¹¹, CH(R^{1'})CONHCH(R^{2'}) CONR¹²R¹³, or CH(R^{1'})CONHCH(R^{2'})(R'), wherein R^{1'} is H or alkyl, heteroalkyl and R^{2'} is phenyl, substituted phenyl, hetero atom-substituted phenyl, thiophenyl, cycloalkyl, piperidyl and pyridyl.


5. (original) The compound of claim 4, wherein R^{1'} is H.

6. (original) The compound of claim 5, wherein

R¹¹ is H or *tert*-butyl;

R' is hydroxymethyl; and

R^{2'} is selected from the group consisting of:



wherein:



U¹ and U² maybe same or different and are independently selected from the group consisting of H, F, CH₂COOH, CH₂COOMe, CH₂CONH₂, CH₂CONHMe, CH₂CONMe₂, azido, amino, hydroxyl, substituted amino, substituted hydroxyl;

U³ and U⁴ maybe same or different and are O or S;

U⁵ is selected from the moieties consisting of alkylsulfonyl, aryl sulfonyl, heteroalkyl sulfonyl, heteroaryl sulfonyl, alkyl carbonyl, aryl carbonyl, heteroalkyl carbonyl, heteroaryl carbonyl, alkoxy carbonyl, aryloxycarbonyl,


heteroaryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl and heteroarylaminocarbonyl or combinations thereof; and

$\text{NR}^{12}\text{R}^{13}$ is selected from the group consisting of:





wherein U^6 is H, OH, or CH₂OH.

7. (original) The compound of claim 2, wherein R² is selected from the group consisting of the following moieties:




8. (original) The compound of claim 7, wherein R³ is selected from the group consisting of:






wherein R^{31} = OH or O-alkyl;


Y^{19} is selected from the following moieties:



and Y^{20} is selected from the following moieties:




9. (original) The compound of claim 8, wherein R^3 is selected from the following structures:





10. (original) The compound of claim 9, wherein Z = N and R⁴ = H.


11. (original) A compound of claim 10, wherein W is C=O, or SO₂.

12. (original) A compound of claim 11, wherein Y is selected from the following moieties:










wherein:

Y^{11} is selected from H, COOH, COOEt, Ome, Ph, Oph, NHMe, NHAc, NHPh, CH(Me)₂, 1-triazolyl, 1-imidazolyl, and NHCH₂COOH;

Y^{12} is selected from H, COOH, COOMe, Ome, F, Cl, or Br;

Y^{13} is selected from the following moieties:




Y^{14} is selected from MeSO₂, Ac, Boc, ⁱBoc, Cbz, or Alloc;

Y^{15} and Y^{16} may be the same or different and are independently selected from alkyl, aryl or heteroalkyl, or heteroaryl;

Y^{17} is CF_3 , NO_2 , $CONH_2$, OH , $COOCH_3$, OCH_3 , OC_6H_5 , C_6H_5 , COC_6H_5 , NH_2 , or $COOH$; and

Y^{18} is $COOCH_3$, NO_2 , $N(CH_3)_2$, F , OCH_3 , CH_2COOH , $COOH$, SO_2NH_2 , or $NHCOCH_3$.

13. (original) A compound of claim 12, wherein Y is selected from the group consisting of:









wherein:

Y¹⁷ = CF₃, NO₂, CONH₂, OH, NH₂, or COOH;


Y¹⁸ = F, COOH,


14. (original) The compound of claim 13, wherein J is selected from the group consisting of:















15. (original) The compound of claim 14 where in J is H, CH₃ or Bn.

16. (original) The compound of claim 15 wherein G is selected from moieties:






Q =










17. (original) The compound of claim 16, wherein G is selected from the group consisting of :



18. (original) A pharmaceutical composition comprising as an active ingredient a compound of claim 1.
19. (previously presented) The pharmaceutical composition of claim 18 suitable for use in treating disorders associated with Hepatitis C virus.
20. (original) The pharmaceutical composition of claim 18 additionally comprising a pharmaceutically acceptable carrier.
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. (previously presented) A compound exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound,


said compound being selected from the group of compounds with structures listed below:





$\mathbf{R} = \mathbf{Me}$

$\mathbf{R} = \mathbf{Benzyl}$




$\mathbf{X} = \mathbf{O}^{\mathbf{t}\mathbf{Bu}}$

$\mathbf{X} = \mathbf{OH}$

$\mathbf{X} = \mathbf{NH}_2$


$\mathbf{X} = \mathbf{NMeOMe}$






$\mathbf{X} = \mathbf{NMe}_2$




$\mathbf{X} = \mathbf{O}^{\mathbf{t}\mathbf{Bu}}$





$\mathbf{X} = \mathbf{OH}$






**X = O^tButyl
X = OH**



$X = O^t\text{Butyl}$ $X = OH$ $X = NMe_2$ 













26. (previously presented) A pharmaceutical composition for treating disorders associated with the hepatitis C virus (HCV) protease, said composition comprising therapeutically effective amount of one or more compounds in claim 25 and a pharmaceutically acceptable carrier.




27. (original) The pharmaceutical composition of claim 26, additionally containing an antiviral agent.

28. (previously presented) The pharmaceutical composition of claim 26 or claim 27, further containing an interferon.


29. (original) The pharmaceutical composition of claim 28, wherein said antiviral agent is ribavirin and said interferon is α -interferon.

30. (previously presented) A compound selected from the group consisting of:





and



or an enantiomer, stereoisomer, rotamer or tautomer thereof, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound exhibits hepatitis C virus (HCV) inhibitory activity.

31. (original) A pharmaceutical composition, comprising one or more compounds of claim 30.

32. (canceled)

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (original) The compound of claim 7, wherein R³ is cyclohexyl.

39. (original) The compound of claim 11, wherein Y is selected from the group consisting of 2-carboxy-3-hydroxyphenyl, 3-tetrahydrofurylmethoxy, and 2-sulfophenyl.

40. (original) The compound of claim 15, wherein G is selected from the group consisting of ethylsulfonylmethyl, phenylsulfonylmethyl, 2-phenylethylsulfonylmethyl and 1-naphthylsulfonylmethyl.